{"title":"The Freedom SOLO bovine pericardial stentless valve","authors":"O. Stanger, H. Tevaearai, T. Carrel","doi":"10.2147/RRCC.S72978","DOIUrl":null,"url":null,"abstract":"Abstract: The third-generation bovine pericardium Freedom SOLO (FS) stentless valve emerged in 2004 as a modified version of the Pericarbon Freedom stentless valve and as a very attractive alternative to stented bioprostheses. The design, choice of tissue, and anticalcification treatment fulfill most, if not all, requirements for an ideal valve substitute. The FS combines the single-suture, subcoronary implantation technique with the latest-generation bovine pericardial tissue and novel anticalcification treatment. The design allows imitation of the native healthy valve through unrestricted adaption to the patient's anatomy, reproducing a normal valve/root complex. However, despite hemodynamic performance superior to stented valves, we are approaching a critical observation period as superior durability, freedom from structural valve deterioration, and nonstructural failure has not been proven as expected. However, optimal performance and freedom from structural valve deterioration depend on correct sizing and perfect symmetric implantation, to ensure low leaflet stress. Any malpositioning can lead to tissue fatigue over time. Furthermore, the potential for better outcomes depends on optimal patient selection and observance of the limitations for the use of stentless valves, particularly for the FS. Clearly, stentless valve implantation techniques are less reproducible and standardized, and require surgeon-dependent experience and skill. Regardless of whether or not stentless valve durability surpasses third-generation stented bioprostheses, they will continue to play a role in the surgical repertoire. This review intends to help practitioners avoid pitfalls, observe limitations, and improve patient selection for optimal long-term outcome with the attractive FS stentless valve.","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"5 1","pages":"349-361"},"PeriodicalIF":0.5000,"publicationDate":"2014-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S72978","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Reports in Clinical Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/RRCC.S72978","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 14
Abstract
Abstract: The third-generation bovine pericardium Freedom SOLO (FS) stentless valve emerged in 2004 as a modified version of the Pericarbon Freedom stentless valve and as a very attractive alternative to stented bioprostheses. The design, choice of tissue, and anticalcification treatment fulfill most, if not all, requirements for an ideal valve substitute. The FS combines the single-suture, subcoronary implantation technique with the latest-generation bovine pericardial tissue and novel anticalcification treatment. The design allows imitation of the native healthy valve through unrestricted adaption to the patient's anatomy, reproducing a normal valve/root complex. However, despite hemodynamic performance superior to stented valves, we are approaching a critical observation period as superior durability, freedom from structural valve deterioration, and nonstructural failure has not been proven as expected. However, optimal performance and freedom from structural valve deterioration depend on correct sizing and perfect symmetric implantation, to ensure low leaflet stress. Any malpositioning can lead to tissue fatigue over time. Furthermore, the potential for better outcomes depends on optimal patient selection and observance of the limitations for the use of stentless valves, particularly for the FS. Clearly, stentless valve implantation techniques are less reproducible and standardized, and require surgeon-dependent experience and skill. Regardless of whether or not stentless valve durability surpasses third-generation stented bioprostheses, they will continue to play a role in the surgical repertoire. This review intends to help practitioners avoid pitfalls, observe limitations, and improve patient selection for optimal long-term outcome with the attractive FS stentless valve.
摘要:第三代牛心包Freedom SOLO (FS)无支架瓣膜于2004年出现,是对periccarbon Freedom无支架瓣膜的改进版本,是一种非常有吸引力的支架生物假体替代品。设计、组织的选择和抗钙化处理,如果不是全部的话,可以满足理想瓣膜替代品的大部分要求。FS将单缝线冠状动脉下植入技术与最新一代牛心包组织和新型抗钙化治疗相结合。该设计允许通过不受限制地适应患者的解剖结构来模仿天然健康瓣膜,再现正常的瓣膜/根复合体。然而,尽管血流动力学性能优于支架式瓣膜,但我们正在接近一个关键的观察期,因为其耐久性、免于结构性瓣膜恶化和非结构性失效尚未得到预期的证实。然而,最佳的性能和免于结构阀的恶化取决于正确的尺寸和完美的对称植入,以确保低叶应力。随着时间的推移,任何姿势不当都会导致组织疲劳。此外,更好的结果取决于最佳的患者选择和对使用无支架瓣膜的限制的遵守,特别是对于FS。显然,无支架瓣膜植入技术的可重复性和标准化程度较低,需要外科医生的经验和技能。无论无支架瓣膜的耐用性是否超过第三代支架生物假体,它们将继续在外科手术中发挥作用。本综述旨在帮助从业者避免陷阱,观察局限性,并改善患者选择具有吸引力的FS无支架瓣膜的最佳长期结果。